Elanco: T. Rowe Price reports 4.5% of common stock
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Elanco Animal Health Inc. (ELAN) common stock is the subject of an amended Schedule 13G in which T. Rowe Price Investment Management, Inc. reported 22,379,405 shares under the form’s aggregate beneficial-ownership field, or 4.5% of the class, as of September 30, 2026. The reporting person listed sole voting power over 22,307,497 shares and sole dispositive power over 22,379,405 shares, with no shared voting or dispositive power. It also stated that the filing is not an admission of beneficial ownership and expressly denied beneficial ownership.
Key Figures
Key Terms
beneficial ownership regulatory
Sole Voting Power regulatory
Sole Dispositive Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.